Advocacy through groups like BCAN and the AUA shapes urologic oncology policy—driving funding, screening access, and equity in cancer care, the authors write.
Feature|Articles|June 30, 2025
What urologists can expect in Q3 of 2025
A comprehensive guide to the key regulatory decisions and conferences slated for Q3 of 2025.
Advertisement
Advertisement
The third quarter of 2025 is set to be a busy one for urology, continuing with the strong momentum from the first half of the year. With notable approvals across bladder cancer, prostate cancer, and other conditions, 2025 has already cemented itself as a landmark year for urology.
Related to this article
The PDUFA target action date is in the fourth quarter of 2026.
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Better detection has changed prostate cancer care. Patients choosing radical treatment still need better protection from the disease returning.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and PCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Sandip Prasad, MD, MPhil, discusses the evolving role of chemoablation in recurrent low-grade, intermediate-risk NMIBC, including patient selection and treatment considerations.
Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
Advertisement
Advertisement